文献速递间质性肺疾病

血栓调节蛋白α治疗特发性肺纤维化急性加重:随机双盲安慰剂对照试验

Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2020-01-01

这项在日本27个中心进行的随机双盲安慰剂对照3期研究纳入特发性肺纤维化急性加重患者,比较血栓调节蛋白α(380 U/kg/d,静脉滴注14天)与安慰剂,所有患者均接受大剂量糖皮质激素治疗。主要终点第90天生存比例在血栓调节蛋白α组为72.5%(29/40),安慰剂组为89.2%(33/37),差异为-16.7个百分点(95%CI -33.8至0.4%;P=0.0863)。结论认为血栓调节蛋白α未改善90天生存比例,结果提示不推荐用于特发性肺纤维化急性加重。

要点

  • 血栓调节蛋白α未改善特发性肺纤维化急性加重患者第90天生存比例。
  • 血栓调节蛋白α组出血不良事件发生率为23.8%(10/42),安慰剂组为10.5%(4/38)。
  • 结果提示不推荐血栓调节蛋白α用于特发性肺纤维化急性加重治疗。

核心结论

  • 血栓调节蛋白α未改善特发性肺纤维化急性加重患者第90天生存比例。
  • 结果提示不推荐血栓调节蛋白α用于特发性肺纤维化急性加重的治疗。

研究设计与样本

  • 随机、双盲、安慰剂对照3期研究,在日本27个中心开展。
  • 纳入特发性肺纤维化急性加重患者,按1:1随机接受安慰剂或血栓调节蛋白α(380 U/kg/d,静脉滴注14天)。
  • 所有受试者均接受大剂量糖皮质激素治疗。
  • 82例随机受试者中77例完成研究并纳入全分析集(血栓调节蛋白α组n=40,安慰剂组n=37)。
  • 安全性人群n=80(血栓调节蛋白α组n=42,安慰剂组n=38)。

主要发现

  • 第90天生存比例:血栓调节蛋白α组72.5%(29/40),安慰剂组89.2%(33/37)。
  • 两组第90天生存比例差异为-16.7个百分点(95%CI -33.8至0.4%;P=0.0863)。
  • 安全性人群中,出血不良事件在血栓调节蛋白α组发生10/42(23.8%),安慰剂组4/38(10.5%)。

临床怎么用

  • 不推荐将血栓调节蛋白α用于特发性肺纤维化急性加重的治疗。
  • 使用血栓调节蛋白α时需关注出血不良事件风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Acute exacerbation during the course of idiopathic pulmonary fibrosis causes a poor prognosis. Coagulation abnormalities and endothelial damage are involved in its pathogenesis. Thrombomodulin alfa, a recombinant human soluble thrombomodulin, has anticoagulant and antiinflammatory effects. Several clinical studies have shown that thrombomodulin alfa may improve survival of acute exacerbation.Objectives: To determine the efficacy and safety of thrombomodulin alfa compared with placebo in acute exacerbation of idiopathic pulmonary fibrosis.Methods: This randomized, double-blind placebo-controlled phase 3 study conducted at 27 sites in Japan involved patients with an acute exacerbation of idiopathic pulmonary fibrosis. Subjects were randomized 1:1 to receive placebo or thrombomodulin alfa (380 U/kg/d for 14 d by intravenous drip infusion). All subjects were treated with high-dose corticosteroid therapy. The primary endpoint was the survival proportion on Day 90.Measurements and Main Results: Of the 82 randomized subjects, 77 completed the study and were included in the full analysis set (thrombomodulin alfa, n = 40; placebo, n = 37). The survival proportions on Day 90 were 72.5% (29 of 40) in the thrombomodulin alfa group and 89.2% (33 of 37) in the placebo group, a difference of -16.7 percentage points (95% confidence interval, -33.8 to 0.4%; P = 0.0863). In the safety population (n = 80), bleeding adverse events occurred in the thrombomodulin alfa group (10 of 42; 23.8%) and the placebo group (4 of 38; 10.5%).Conclusions: Thrombomodulin alfa did not improve the 90-day survival proportion. The present results suggest that the use of thrombomodulin alfa for the treatment of acute exacerbation of idiopathic pulmonary fibrosis not be recommended.Clinical trial registered with www.clinicaltrials.gov (NCT02739165).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Kondoh Y, Azuma A, Inoue Y, et al. Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial. Am J Respir Crit Care Med. 2020. PMID: 31917621. doi:10.1164/rccm.201909-1818OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。